Amarin Corporation PLC (AMRN) CEO John Thero on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
Matinas BioPharma And Amarin In Hypertriglyceridemia: The Head-To-Head Phase 2 StudySeeking Alpha • 10/25/19
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Patients at High Risk of Cardiovascular Events, such as Heart Attack, Stroke and Cardiac DeathGlobeNewsWire • 10/17/19
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on StatinsGlobeNewsWire • 09/16/19